Department of Developmental Neurology, Medical University of Gdansk, Poland.
Neurol Neurochir Pol. 2022;56(1):14-20. doi: 10.5603/PJNNS.a2022.0020. Epub 2022 Feb 25.
Cannabis sativa has been cultivated for human use for about 5,000 years, and has likewise been used in the treatment of epilepsy for thousands of years.
Cannabidiol (CBD), which was isolated from cannabis sativa in 1940, has an anti-seizure effect and no psychoactive activity. Its effectiveness in reducing various types of seizures has been proven in animal seizure and epilepsy models. Recent randomised, placebo-controlled trials have confirmed its effectiveness in patients with drug-resistant epilepsy.
The aim of this position paper was to present the specific mechanism of CBD's anti-seizure action and current indications for CBD's use in epilepsy. The only cannabis-derived drug that has successfully passed clinical trials and has obtained United States Food and Drug Administration and European Medicines Agency approval for epilepsy is Epidiolex®. This paper presents the outcomes of the completed clinical trials with the use of this drug.
CBD may be an effective drug in drug-resistant epilepsy, particularly in Dravet Syndrome, Lennox- Gastaut Syndrome and seizures associated with tuberous sclerosis complex. Additional randomised, placebo-controlled studies with CBD are needed.
人类种植大麻已有约 5000 年的历史，同样也用其治疗癫痫已有数千年。
大麻二酚（CBD）于 1940 年从大麻中分离出来，具有抗惊厥作用，没有精神活性。其在减少各种类型惊厥发作方面的有效性已在动物惊厥和癫痫模型中得到证实。最近的随机、安慰剂对照试验证实了其在耐药性癫痫患者中的有效性。
本立场文件旨在介绍 CBD 抗惊厥作用的具体机制以及 CBD 在癫痫中的当前应用指征。唯一一种成功通过临床试验并获得美国食品和药物管理局以及欧洲药品管理局批准用于治疗癫痫的大麻衍生药物是 Epidiolex®。本文介绍了使用该药物完成的临床试验结果。
CBD 可能是治疗耐药性癫痫的有效药物，特别是在 Dravet 综合征、Lennox-Gastaut 综合征和与结节性硬化症相关的癫痫发作中。需要进行更多的 CBD 随机、安慰剂对照研究。
Zotero 插件